These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 12206969)
21. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates. Ostrer L; Khodursky RF; Johnson JR; Hiasa H; Khodursky A Int J Antimicrob Agents; 2019 Mar; 53(3):318-324. PubMed ID: 30582984 [TBL] [Abstract][Full Text] [Related]
22. Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. Hooper DC; Jacoby GA Cold Spring Harb Perspect Med; 2016 Sep; 6(9):. PubMed ID: 27449972 [TBL] [Abstract][Full Text] [Related]
23. Emerging mechanisms of fluoroquinolone resistance. Hooper DC Emerg Infect Dis; 2001; 7(2):337-41. PubMed ID: 11294736 [TBL] [Abstract][Full Text] [Related]
24. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428 [TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in Salmonella enterica typhimurium isolates in humans. Casin I; Breuil J; Darchis JP; Guelpa C; Collatz E Emerg Infect Dis; 2003 Nov; 9(11):1455-7. PubMed ID: 14718091 [TBL] [Abstract][Full Text] [Related]
26. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Pfaller MA; Jones RN Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036 [TBL] [Abstract][Full Text] [Related]
27. Mechanisms of action and resistance of older and newer fluoroquinolones. Hooper DC Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324 [TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Huband MD; Cohen MA; Zurack M; Hanna DL; Skerlos LA; Sulavik MC; Gibson GW; Gage JW; Ellsworth E; Stier MA; Gracheck SJ Antimicrob Agents Chemother; 2007 Apr; 51(4):1191-201. PubMed ID: 17261623 [TBL] [Abstract][Full Text] [Related]
29. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types. Billal DS; Fedorko DP; Yan SS; Hotomi M; Fujihara K; Nelson N; Yamanaka N J Antimicrob Chemother; 2007 Jan; 59(1):28-34. PubMed ID: 17065188 [TBL] [Abstract][Full Text] [Related]
30. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV. Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166 [TBL] [Abstract][Full Text] [Related]
31. [MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones]. Malakhova MV; Vereshchagin VA; Il'ina EN; Govorun VM; Filimonova OIu; Grudinina SA; Sidorenko SV Antibiot Khimioter; 2007; 52(1-2):10-7. PubMed ID: 18461803 [TBL] [Abstract][Full Text] [Related]